Last reviewed · How we verify
long acting beta agonist
long acting beta agonist is a Long-acting beta-2 agonist (LABA) Small molecule drug developed by University of Alberta. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: Serevent, Oxeze.
Long-acting beta agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing prolonged relaxation and bronchodilation.
Long-acting beta agonists are small molecule medications used to treat conditions such as asthma, chest syndrome, and lung function issues. They are often administered in combination with inhaled corticosteroids and may be used to treat other conditions including clinical anxiety and depression.
At a glance
| Generic name | long acting beta agonist |
|---|---|
| Also known as | Serevent, Oxeze |
| Sponsor | University of Alberta |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
LABAs activate beta-2 adrenergic receptors, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation. This effect is sustained for 12-24 hours depending on the specific agent, making them suitable for maintenance therapy in chronic respiratory conditions. They are typically used in combination with inhaled corticosteroids to reduce exacerbations and improve lung function.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness/anxiety
Key clinical trials
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma (PHASE2)
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- Fractional Exhaled Nitric Oxide and Exacerbations of COPD
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- long acting beta agonist CI brief — competitive landscape report
- long acting beta agonist updates RSS · CI watch RSS
- University of Alberta portfolio CI
Frequently asked questions about long acting beta agonist
What is long acting beta agonist?
How does long acting beta agonist work?
What is long acting beta agonist used for?
Who makes long acting beta agonist?
Is long acting beta agonist also known as anything else?
What drug class is long acting beta agonist in?
What development phase is long acting beta agonist in?
What are the side effects of long acting beta agonist?
What does long acting beta agonist target?
Related
- Drug class: All Long-acting beta-2 agonist (LABA) drugs
- Target: All drugs targeting Beta-2 adrenergic receptor
- Manufacturer: University of Alberta — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Also known as: Serevent, Oxeze
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing